

***PHARMACOLOGY***  
***BIOCHEMISTRY***  
***AND***  
***BEHAVIOR***

**VOLUME 49, 1994**  
**SUBJECT AND AUTHOR INDEX**



**PERGAMON**

# PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital  
P.O. Box 3448, London SE1 9QH, UK

---

## Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland  
LEMBIT ALLIKMETS, Tartu, Estonia  
ROBERT L. BALSTER, Richmond, VA  
GIOVANNI BIGGIO, Cagliari, Italy  
MIKE BRILEY, Castres, France  
ALLAN C. COLLINS, Boulder, CO  
DONALD V. COSCINA, Toronto, Ontario, Canada  
JACQUELINE N. CRAWLEY, Bethesda, MD  
ANNETTE DOMENEY, Geneva, Switzerland  
ADRIAN J. DUNN, Shreveport, LA  
BURR EICHELMAN, Philadelphia, PA  
WILLIAM J. FREED, Washington, DC  
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain  
RICHARD A. GLENNON, Richmond, VA  
F. G. GRAEFF, São Paulo, Brazil  
M. R. C. GREENWOOD, Davis, CA  
ROLAND R. GRIFFITHS, Baltimore, MD  
STEPHEN G. HOLTZMAN, Atlanta, GA  
AKIRA HORITA, Seattle, WA  
CHRIS E. JOHANSON, Baltimore, MD  
HAROLD KALANT, Toronto, Ontario, Canada  
G. JEAN KANT, Washington, DC  
KATHLEEN M. KANTAK, Boston, MA  
GEORGE F. KOOB, La Jolla, CA

CONAN KORNETSKY, Boston, MA  
J. DAVID LEANDER, Indianapolis, IN  
EMINY H. Y. LEE, Taipei, Taiwan  
ALLEN S. LEVINE, Minneapolis, MN  
WILLIAM J. McBRIDE, Indianapolis, IN  
DONALD E. McMILLAN, Little Rock, AR  
JACK H. MENDELSON, Belmont, MA  
FATHY S. MESSIHA, Grand Forks, ND  
ROBERT D. MYERS, Greenville, NC  
JUDITH A. PRATT, Glasgow, UK  
JAQUELINE SAGEN, Chicago, IL  
ROSARIO SAMANIN, Milan, Italy  
HERMAN H. SAMSON, Winston-Salem, NC  
PAUL R. SANBERG, Tampa, FL  
PHIL J. SKOLNICK, Bethesda, MD  
LINDA P. SPEAR, Binghamton, NY  
CLARE STANFORD, London, UK  
MARIE-HÉLÈNE THIÉBOT, Paris, France  
DEREK VAN DER KOOY, Toronto, Ontario, Canada  
JEANNE M. WEHNER, Boulder, CO  
BRUNO E. WILL, Strasbourg, France  
J. C. WINTER, Buffalo, NY  
ALICE M. YOUNG, Detroit, MI  
IAN S. ZAGON, Hershey, PA

---

## PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

*US Editorial Office:*

Matthew J. Wayner

Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West  
San Antonio, TX 78249-0662

Fax: (210) 691-4510

*European Editorial Office:*

Sandra E. File

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital  
P.O. Box 3448, London SE1 9QH, UK

Fax: 44-(0)71-955-4627; E-mail: S.FILE@UMDS.AC.UK

*Production Editor:*

Alayne A. Bakken

E-mail: A.BAKKEN@ELSEVIER.COM

*Publishing, Subscription, and Advertising Offices:*

Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:  
ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington,  
Oxford OX5 1GB, England

*Published Monthly*

*Annual Institutional Subscription Rates (1995):* North, Central and South America, US\$1580.00, Rest of World £1060.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

*Pharmacology Biochemistry and Behavior* is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-0662, USA. E-mail: EDITOFF@LONESTAR.UTSA.EDU; Fax: (210) 691-4510. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.



## SUBJECT INDEX

- Abuse liability, 643  
Acetylcholine, 769, 807, 1067, 1075  
Acoustic startle, 877, 935  
Acquisition, 935  
Acrylamide, 443  
Active avoidance, 33  
Activity feedback, 975  
Adaptation, 247  
Adenosine, 271  
Adenosine A<sub>1</sub> receptors, 271  
Adenosine A<sub>2</sub> receptors, 271  
Adrenergic, 295  
Adrenocortical stress response, 961  
AF64A (ethyl choline mustard aziridinium), 33  
Affective-motivational, 827  
Age, 371, 497  
Aged rats, 1075  
Aggression, 313, 483  
Aggressive behavior, 13  
Aging monkeys, 235  
Aging, 213, 683  
Agonists, 295  
AHR 11797, 47  
 $\alpha_1$ -Adrenergic receptors, 897  
 $\alpha_2$ -Adrenoceptors, 79  
 $\alpha_2$  Agonists, 579  
Alcogene, 417  
Alcohol, 629  
Alcohol drinking, 949  
Alcohol intake, 417  
Alcohol preference, 7  
Alcohol withdrawal, 561  
Alcoholism, 949  
Aldehyde adduct, 949  
Alfentanil, 523  
Alkylation, 621  
Alpha<sub>2</sub>-adrenergic antagonist, 523  
Alzheimer's disease, 769  
Ambulatory activity, 323  
Aminophylline-induced convulsions, 609  
Amnesia, 849  
Amnesia models, 859  
Amphetamine, 41, 133, 497, 819  
Amygdala, 359, 1113  
Anabolic steroids, 313  
Analgesia, 303, 827, 1029  
Anesthesia, 523  
Anesthetic, 1061  
Animal communication, 835  
Animal model, 549, 683  
Anorectic agent, 287  
Antagonists, 295, 573  
Anterior hypothalamic-preoptic area, 835  
Anticholinergic, 363, 813  
Anticholinesterase, 363  
Anticipatory vomiting, 385  
Anticonvulsant, 1113  
Anticonvulsant test, 47  
Antidepressants, 263, 281  
Antiinflammatory, 335  
Antinociception, 649, 657, 675, 929, 1093  
Anxiety, 327, 359, 393, 471, 549, 755, 801, 911  
Anxiogenic drugs, 171  
Anxiolytic-like effect, 101  
Anxiolytics, 171, 281, 741  
Apomorphine, 819  
Appetite, 187  
Arcuate nucleus, 579  
Area postrema, 489  
Arterial blood pressure, 489  
Associative tolerance, 1029  
Atipamezole, 523  
Atropine, 1, 115  
Attention, 683  
Autoradiography, 7  
Autoshaping, 1083  
Avoidance behavior, 1075  
  
Baclofen, 561  
Balb/c, 433  
Baroreflex, 489  
Basal ganglia, 437  
Basal magnocellular nucleus, 33  
Behavior, 701, 795  
Behavioral despair, 891  
Behavioral performance, 781  
Behavioral pharmacology, 1049  
Behavioral sensitization, 241, 247, 583  
Behavioral thermoregulation, 747  
Behavioral toxicity, 503  
Behavioural activity types, 263  
Benzodiazepines, 359, 477, 625, 827, 921, 1113  
Benzodiazepine receptors, 253  
 $\beta$ -Carboline, 949  
 $\beta$ -Endorphin, 1037  
 $\beta_1$ -Adrenoceptors, 13  
 $\beta_2$ -Adrenoceptors, 13  
Blood-brain barrier, 341  
Body temperature, 531  
BPBA, 561  
Bradykinesia, 19  
Brain and plasma concentrations, 287  
Brain regions, 905  
Bromocriptine, 969  
Buprenorphine, 241, 1017  
Buspirone, 741  
Butorphanol, 649, 657, 843  
  
C57BL/6, 1109  
Ca<sup>2+</sup> signal, 669  
Calcium, 1093  
Calcium transients, 405  
Calories, 629  
cAMP, 1093  
Cannabinoids, 929, 1093  
Capsaicin-sensitive nerves, 253  
Carbachol, 835  
Cardiac arrest, 129  
Cat odor, 219  
Catalepsy, 277  
Catecholamines, 33, 599  
CCK-B agonists, 133  
CCK-B antagonists, 433  
CCK-B receptors, 133  
Central benzodiazepine binding, 47  
Central benzodiazepine receptor heterogeneity, 47  
Central locomotor activity (antiagoraphobic Inhibition), 711  
Central injection, 463  
Cerebellar grafts, 443  
Cerebellum, 639, 777  
Cerebrolysin, 1105  
Cerebrospinal fluid, 997  
CGP 35348, 561  
CGS 9896, 47  
Change in diameter, 891  
Chicks, 73, 1011  
Chickadee, 363  
Chlorambucil, 621  
Chlordiazepoxide, 133  
Cholecystokinin, 133  
Cholecystokinin (CCK) receptors, 463  
Cholesterol, 257  
Choline acetyltransferase, 33  
Cholinergic, 1, 511  
Cholinergic system development, 1043  
Cholinesterase, 235  
Chronic aminophylline, 609  
Chronic phenobarbital, 427  
Chronic tolerance, 371  
Chronic treatment, 859  
Circadian, 327  
Circadian rhythms, 975, 997  
Circumventricular organ, 489  
Cl<sup>-</sup> influx, 477  
Classical conditioning, 147, 583, 1061  
Clenbuterol, 13  
Clonidine, 79, 579, 849  
Clozapine, 115, 165, 1025  
Cocaine, 107, 177, 223, 229, 247, 345, 555, 583, 711, 935, 1001, 1007  
Cocaine withdrawal, 223, 883  
Cognition, 683

- Compensatory response, 1029  
 Condensation product, 949  
 Conditioned avoidance responses, 819  
 Conditioned fear stress, 911  
 Conditioned place preference, 241, 1001  
 Context, 763  
 Context fear conditioning, 183  
 Continent tolerance, 1113  
 Continuous stress, 905  
 Convulsions, 561, 1113  
 Core temperature, 747  
 Cortical activation, 235  
 Cortical slow waves, 235  
 Corticosterone, 287, 729  
 Cortisol, 583  
 Counting, 943  
 CPT, 271  
 Cross tolerance, 455, 657
- D<sub>1</sub> receptors, 73, 165, 197, 205  
 D<sub>2</sub> receptors, 73, 165, 197, 205  
 D<sub>2</sub> receptor antagonist, 19  
 DA autoreceptor antagonist, 345  
 DAGO, 737  
*d*-Amphetamine, 345  
 DBA/2, 1109  
 DBA/2Ibg inbred mice, 257  
 Defense, 541  
 Defensive behavior, 741  
 Delayed matching to position, 1067  
 Delayed matching to sample, 427  
 Delayed nonmatching to position, 1067  
 $\delta$ -Opioid receptor, 795, 1109  
 $\delta_1$  opioid receptors, 1109  
 $\delta_2$  opioid receptors, 1109  
 $\Delta^9$ -Tetrahydrocannabinol, 763  
 Delta opioid receptors, 675  
 Dependence, 455  
 Depression, 165, 353, 759  
 Descending pathway, 675  
 Desipramine, 13  
 Development, 353, 997  
 Dexamethasone, 335  
 Dexamethasone suppression test, 961  
 Dexfenfluramine, 287  
 Dexmedetomidine, 523  
 Diabetes, 669  
 Diazepam, 253, 393, 549, 561, 609, 755, 1113  
 Dietary fat content, 287  
 Dihydro- $\beta$ -erythroidine, 1  
 Dipeptidyl endopeptidases, 33  
 Discrimination learning, 213  
 Distress vocalizations, 327, 1011  
 Dizocilpine, 489, 943, 1049  
 DOI, 129, 165, 229  
 DOM, 115  
 Domestic chicks, 483  
 Domestic fowl, 1011  
 Dopamine (DA), 25, 73, 85, 107, 147, 353, 567, 711, 911, 969, 985  
 Dopamine agonist, 901  
 Dopamine D<sub>2</sub> antagonist, 323  
 Dopamine receptors, 247, 567  
 Dopaminergic neuron, 807  
 Dopaminergic systems, 819  
 Dorsal raphe, 555  
 DPAT, 93  
 DPDPE, 675, 795  
 Drinking, 417  
 Drinking behavior, 1
- Drug dependence, 1049  
 Drug discrimination, 223, 955  
 Drug interaction, 335  
 Drug reward, 241  
 Drug self-administration, 233  
 Drug tolerance, 1049  
 DSLET, 1109  
 DSP-4, 541  
 DTG, 385  
 DuP 996, 1067, 1075
- Early protein malnutrition, 393  
 ECoG, 235  
 Ectodermal microceptor preparation, 777  
 EEG, 235, 781, 795  
 8-Hydroxy-2-(di-*n*-propylamino)tetralin, 7  
 Electric foot shock stress, 471  
 Electroconvulsive shock, 849  
 Electrophysiology, 555  
 Elevated plus-maze, 133, 171, 801, 985  
 Elevated T-maze, 549  
 Emesis, 385  
 Endocrine effects, 583  
 Enriched environment, 393  
 Environmentally induced oral stereotypies, 295  
 Estradiol, 819  
 Ethanol, 371, 413, 417, 789  
 Ethanol preference, 949  
 Ethanol withdrawal syndrome, 969  
 Ethological analysis, 541, 985  
 Etorphine, 773  
 Excitatory amino acids antagonists, 413  
 Excitatory synaptic transmission, 1105  
 Exploration, 449  
 Exploratory activity, 801  
 Extinction, 935  
 Extrapyramidal motor system, 437  
 Extrapyramidal side effects, 19
- F-344 rats, 1057  
 Factor analysis, 171  
 Fawn-Hooded rat, 759  
 Fear conditioning, 935  
 Feeding, 25, 85, 143, 377, 737, 843, 853  
 Feeding pattern, 629  
 Fentanyl, 773, 1017  
 Fetus, 795  
 Fever, 747  
 FG 7142, 133  
 50-kHz calls, 835  
 5,7-Dihydroxytryptamine, 177  
 5-HT, 359  
 5-HT<sub>1A</sub>, 1083  
 5-HT<sub>1A</sub> agonist, 385  
 5-HT<sub>2</sub> receptors, 107, 129, 165  
 5-HT<sub>2</sub> receptor antagonist, 19  
 5-HT<sub>3</sub> antagonists, 67, 385  
 5-HT, 449  
 5-HT release, 1037  
 Fixed-ratio, 1049  
 Flavored solutions, 417  
 Flunitrazepam, 47  
 Fluoxetine, 121  
 Flupenthixol, 883  
 Food caching, 363  
 Food carrying, 741  
 Food deprivation, 197  
 Food intake, 187, 759, 897  
 Food restriction, 295  
 Foot shock stress, 911  
 Foraging, 741
- Forced swim, 729  
 Forced swimming test, 79  
 Forgetting functions, 427  
 Forskolin, 1093  
 Fourier analysis, 813  
 Fowls, 295  
 Free exploration test, 433  
 Freely moving rat paradigm, 711  
 Freezing, 183  
 Freezing behavior, 911  
 Frog, 277  
 Frontal cortex, 599  
 Functional and metabolic tolerance, 371
- GABA, 303, 359, 449  
 GABA agonists, 589  
 GABA antagonists, 589  
 GABA<sub>B</sub> receptor, 561  
 GABA-ergic functions, 443  
 GABA-transaminase, 801  
 Gamma-vinyl GABA, 801  
 Gastric emptying, 253  
 Gastric smooth muscle, 669  
 GBR 12909, 345  
 Generalized anxiety, 219  
 Genetics, 417, 531, 663  
 Genetic differences, 975  
 Genetic model, 165  
 Glucocorticoid receptor, 961  
 Glucoprivation, 853  
 Glutamate, 835  
 Glutamatergic-cholinergic interactions, 689  
 Glycine, 303  
 Glycine receptor, 707  
 Gnawing, 737  
 Growth hormone, 165  
 Guinea pig, 133
- H-7, 669  
 Habenula, 555  
 Habituation, 449  
 HAD rats, 417  
 Haldol®, 223  
 Hallucinogens, 599  
 Haloperidol, 197, 205, 223, 309, 813, 969  
 Handling, 393, 449  
 Harman, 949  
 Head-shake response, 107  
 Head-twitch response, 229  
 Heart rates, 489, 629, 747  
 Heritability, 531  
 Hexamethonium, 1  
 HI-6, 781  
 High-affinity choline uptake, 689  
 Hippocampal slices, 1105  
 Hippocampus, 359, 599, 949  
 Histamine, 853  
 HL $\delta$ -7, 781  
 Hot plate, 701, 737  
 Human, 573, 643, 763  
 Hydrocortisone, 335  
 Hyperalgesia, 701, 1029  
 Hyperphagia, 47  
 Hypnosis, 371  
 Hypothermia, 47, 371  
 Hypoxia, 129
- Ibogaine, 711  
 Ibotenic acid, 33  
 Ibuprofen, 335  
 ICI118,551, 13

- ICS 205-930, 67  
 ICSS, 901  
 ICSS paradigm, 345  
 Immediate-shock deficit, 183  
 Immobility time, 729  
 Immobilization stress, 471  
 In vivo electrochemistry (Voltammetry), 711  
 In vivo receptor binding, 165  
 Inbred mice, 271  
 Inbred strains, 975  
 Induced seizures, 335  
 Inhibitors, 235  
 Initial discriminability, 427  
 Inositol, 341  
 Instrumental behavior, 85  
 Interaction, 511  
 Intermediate stage, 921  
 Intermittent stress, 905  
 Intracellular calcium, 1087  
 Intracerebroventricular, 657, 1093  
 Intracerebroventricular infusion, 649  
 Intracerebroventricular injections, 309  
 Intrathecal, 303, 1093  
 Intrathecal administration, 929  
 Intravenous, 1029  
 Ipsapirone, 165, 549  
 Ischemia, 129  
 Isolation, 13  
 Isolation distress, 327  
 Isolation stress, 1011  
 IV surgery, 233
- Jugular catheterization, 233
- Kainic acid, 33  
 Kappa receptor subtypes, 929  
 Ketamine, 1061  
 Ketanserin, 129, 849  
 Kindling, 1113
- LAD, 417  
 Latency, 891  
 Layer 5, 639  
 Learning, 147, 1061, 1083  
 Learning and memory, 807  
 Lesion, 511  
 LH, 789  
 Li-pilocarpine seizures, 341  
 Licking, 813  
 Light/dark choice test, 433  
 Limbic system, 949  
 Linopirdine, 1067, 1075  
 Lithium, 341, 975, 1087  
 Lobeline, 877  
 Locomotion in open field, 47  
 Locomotor activity, 41, 67, 101, 241, 271, 531, 711, 1043  
 Locus coeruleus, 541  
 Long-term potentiation, 707  
 Long-term treatment, 263  
 LSD, 115  
 Lurcher mutants, 777
- Male sexual behavior, 303  
 Marijuana, 187, 643, 763  
 Maternal deprivation, 961  
 Maternal induction behavior, 871  
 Maximal electroshock, 609  
 mCPP, 93, 165, 759  
 MDL 72222, 67  
 Mecamylamine, 1, 859, 877
- Medial prefrontal cortex, 911  
 Mefenamic acid, 335  
 Melatonin, 327  
 Memory, 363, 549, 707, 849, 1061  
 Meperidine, 1017  
 Methadone, 143, 955, 1101  
 Methadone dependent, 1101  
 Methamphetamine sensitization, 323  
 Methlycarbamylocholine, 1  
 Methylenedioxyamphetamine, 599  
 Methylhistamine, 853  
 Metoprolol, 13  
 Metyrapone, 729  
 Mice, 13, 263, 323, 433  
 Microdialysis, 25, 107  
 MK-801, 489, 1049  
 MK-801-induced amnesia, 859  
 Monoamine depletion, 79  
 Monoamine metabolism, 471  
 Monoaminergic interactions, 541  
 Monoaminergic receptor, 961  
 Morphine, 649, 657, 737, 773, 1011, 1017, 1029, 1037  
 Morphine dependence, 1109  
 Morris water maze, 1075  
 Morris water task, 257  
 Motivation, 25, 85  
 Motor activity, 747  
 Motor control, 25  
 Motor reflex, 827  
 Mouse, 133, 689, 701, 871, 1043  
 Movement initiation, 777  
 $\mu$ -opioid receptors, 1109  
 Muscarinic receptors, 405  
 Muscle rigidity, 523  
 Muscle tone, 523  
 Myoclonus, 129
- Naloxone, 183, 377, 573, 1011  
 Naloxone benzoylhydrazone, 929  
 Naloxone withdrawal, 1109  
 Naltrexone, 197, 205, 589  
 Naltrindole, 795  
 NAN-190, 385  
 Narcotics, 827  
 NECA, 271  
 Neonate, 1017  
 Neophobia, 433  
 Nerve agent, 503  
 Nerve growth factor, 701, 1043  
 Neurobehavioral ontogeny, 1043  
 Neurochemistry, 1075  
 Neuroleptics, 19, 813  
 Neuromodulation, 443  
 Neurotoxicity, 335  
 Nicotine, 1, 511, 531, 755, 769, 807, 877  
 Nicotine reinforcement, 67  
 Nictitating membrane response, 1061  
 Nitrous oxide, 573  
 NMDA receptor, 707  
 N-Methylcarbamylocholine phosphoinoside, 405  
 N-Methyl-D-aspartate, 489  
 N-methyl-D-aspartate receptor, 859  
 Nociception, 303, 737827  
 Nootropics, 263  
 Nor-binaltorphimine, 929  
 Noradrenaline, 13, 303, 541  
 Noradrenaline turnover, 905  
 Noradrenergic, 511  
 Norepinephrine, 57  
 NSAID, 335
- Nucleus accumbens (NAcc), 85, 155, 711  
 Nucleus tractus solitarius, 489
- Offense, 541  
 1-Amino-5-bromouracil (ABU), 471  
 1-Methyl- $\beta$ -carboline, 949  
 One trial, 183  
 Open field, 801, 263  
 Open-field test, 961  
 Operant, 25, 143, 843  
 Operant behavior, 943  
 Operant feeding, 463  
 Operant reinforcement, 377  
 Opiates, 143, 303, 377, 523, 573, 579, 843  
 Opioid analgesia, 183, 773  
 Opioid mixed agonist-antagonist, 241  
 Opioid receptors, 773  
 Opioids, 197, 205, 327, 573, 625, 795, 1011  
 Organ weights, 905  
 Organophosphate, 747  
 Organophosphate cholinesterase, 503  
 Osmotic minipump, 649, 657, 949  
 Ovariectomy, 819  
 Oxazepam, 871  
 Oxytocin, 101
- p*-Chlorophenylalanine (PCPA), 483  
 P Rats, 417  
 Paeoniflorin, 213  
 Pain, 303, 701, 1011  
 Pain control system (descending), tolerance, 1037  
 Palatability, 417  
 Paradoxical sleep, 921  
 Paragigantocellularis, 121  
 Parkinson-like, 813  
 Parkinson's disease, 147  
 Parkinsonism, 437  
 Paroxetine, 281  
*Parus atricapillus*, 363  
 Passive avoidance, 33, 849  
 Passive avoidance task, 807  
 Passive avoidance test, 859  
 Pavlovian facilitator, 955  
 PD135158, 433  
 Pentobarbital, 589  
 Peptides, 1105  
 Percentile schedules, 943  
 Performance, 497, 827  
 Perioral movements, 437  
 Pertussis toxin, 773  
 PGO waves, 93  
 Phaclofen, 561  
 Pharmacodynamics, 335  
 Phencyclidine, 1025  
 Photo-phobic test, 541  
 Physical activities, 629  
 Physostigmine, 363, 1067  
 Picrotoxin, 589  
 Pigeons, 385, 955  
 Pigs, 463  
 Piracetam, 683  
 Place approach, 1001  
 Plasma corticosterone, 905  
 Platelets, 1087  
 Plus-maze test, 47  
 Polydipsia, 1  
 Postintoxication incapacitation, 781  
 Posttreatment, 323  
 Potency, 643  
 PRE-084, 859  
 Preference, 417

- Pregnancy, 795  
 Pregnant, 1101  
 Prenatal pup treatment, 871  
 Proactive interference, 427  
 Prolactin, 583, 789  
 Prolyl endopeptidase, 33  
 Propranolol, 13  
 Protective drugs, 503  
 Protein kinase C, 669  
 Psychological stress, 911  
 Psychomotor, 573  
 Psychostimulant behavior, 711  
 Pulsatile secretion, 789  
 Purkinje cells, 443  
 Pygmy goats, 897  
 Pyridostigmine, 503
- Quail, 625  
 Quinpirole, 73, 155, 197, 205, 985
- Rabbit, 599, 1061  
 Radioligand binding, 271, 625  
 Rapid eye movement (REM) sleep, 93, 413  
 Rats, 41, 115, 133, 171, 223, 281, 309, 393, 417, 497, 541, 555, 589, 663, 729, 741, 807, 813, 835, 849, 883, 921, 969, 1001, 1007, 1049, 1067, 1075, 1083, 1087, 1101, 1105, 1113  
 Rate of forgetting, 427  
 Rearing behavior, 711  
 Receptors, 1083  
 Receptor plasticity, 247  
 Receptor subtypes, 295  
 Rectal temperature, 165  
 Regression residuals, 531  
 Reinforcement, 25, 763, 843  
 Reinforcement density, 943  
 Reinforcement loss, 943  
 Reinforcing effects, 643  
 REM sleep deprivation, 79  
 Reserpine, 73, 229  
 Respiration, 1011  
 Response rate, 943  
 Retention, 1061  
 Rhesus macaque, 503  
 Risk assessment, 985  
 RJM, 663  
 RMI-81582, 165  
 Ro15-1788, 47  
 Rotarod performance, 443  
 Rotation, 147  
 Run length, 943  
 Running-wheel, 263
- Satiety, 187  
 SCH-23390, 197, 205, 807, 985  
 SCH 39166, 567  
 Schedule-controlled behavior, 589, 1049  
 Schizophrenia, 155, 877  
 Scopolamine, 133, 363, 807, 813, 1043, 1067
- Security of implantation, 639  
 Sedation, 101  
 Seizure, 1113  
 Selective breeding, 531  
 Self-administration, 177, 643, 763  
 Self-stimulation, 901  
 Senescence-accelerated mice (SAM), 769  
 Sensitization, 883, 935  
 Sensorimotor gating, 155, 877  
 Sensory-discriminative, 827  
 Septo-hippocampal pathway, 689  
 Septum, 689  
 Serotonergic drugs, 313  
 Serotonin, 57, 93, 107, 121, 129, 177, 303, 483, 599, 759, 849, 911, 1083  
 Serotonin (5-HT), 555, 711, 741  
 Serotonin receptors, 115  
 Serotonin-1A receptors, 7  
 Sexual behavior, 121  
 Sexual exhaustion, 121  
 Short-term memory, 683  
 $\sigma$  sites, 859  
 Simple phobia, 219  
 Single-unit recording, 555  
 SKF-38393, 73, 197, 205, 985  
 Sleep, 93, 921  
 Sleep-like states, 277  
 Slow-wave sleep, 413  
 SM-9018, 19  
 Social interaction model, 281  
 Soda, 629  
 Soman, 503, 781  
 Spatial learning, 707  
 Spatial navigation/memory, 1075  
 Spatial reference memory, 689  
 Spinal analgesia, 773  
 Spinal cord, 303, 1037  
 Spinal GABA, 675  
 Spinocerebellar ataxia, 443  
 Startle, 155, 1025  
 State anxiety, 433  
 Steady state, 287  
 Stearate microelectrode, 711  
 Stereotypy, 711  
 Steroids, 335  
 Stimulus control, 115  
 Strains, 57  
 Stress, 57, 353, 449, 737  
 Stress intensity, 911  
 Stress-rest cyclicality, 905  
 Striatum, 147  
 Subcutaneous, 1029  
 Subcutaneous administration, 1007  
 Subjective, 573  
 Subjective effects, 643, 763  
 Subsensitive, 165  
 Substantia nigra, 147, 737  
 Subtypes, 133  
 Suckling, 1043  
 Sulpiride, 807, 985
- Supraspinal, 1037  
 Supraspinal analgesia, 773  
 Surgical method, 233  
 Surgical procedure, 639  
 Swim test, 41  
 Swimming activity, 79  
 Synaptosomes, 1093
- Tabun, 781  
 Tacrine, 213  
 Tail flick, 737  
 Tail pinch, 737  
 Tardive dyskinesia, 309, 663  
 Tele-methylhistamine, 997  
 Telemetry, 747  
 Testosterone propionate, 313  
 THC, 643  
 Theophylline, 335  
 Thermal nociception, 1011  
 Thermogenesis, 1057  
 Thermoregulation, 1011  
 Threshold, 827  
 Thrombin, 1087  
 Time course study, 165  
 Tobacco, 769  
 Tolerance, 287, 455, 477, 609, 649, 883, 1029, 1037  
 Tolerance dissipation, 1113  
 Tongue, 813  
 Tonic immobility, 625  
 Tonic nociception, 1017  
 Trait anxiety, 433  
 Transfected M<sub>1</sub> gene, 405  
 Treadmill running, 1057  
 Tremor, 561  
 Triazolam, 455  
 Tryptophan hydroxylase, 277  
 22-kHz calls, 835  
 2-Deoxy-D-glucose, 205, 853
- (+)-UH232, 345  
 U-50,488, 657  
 U50,488H, 929  
 Ultrasonic vocalization, 835
- Vacuous chewing movements, 309  
 Vasopressin, 897  
 Vigabatrin, 801  
 Vigilance, 497  
 Vocalizations, 827  
 Volunteer, 573
- Water maze, 511  
 Withdrawal, 41, 253
- Y-maze test, 859  
 YM-09151-2, 323
- Zinc, 477  
 Zolpidem, 47, 455

# PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 49 1994

## AUTHOR INDEX

- Abood, L. G., 405  
Adegboyega, P. A., 1087  
Adell, A., 949  
Afargan, M., 335  
Agam, G., 341  
Agrawal, A. K., 443  
Ahlenius, S., 101  
Airaksinen, E. M., 997  
Akarsu, E. S., 969  
Alleva, E., 701, 871  
Almeida, S. S., 393  
Aloe, L., 701  
Alonso, S. J., 353  
Alster, P., 101  
Andreassen, O. A., 309  
Andrews, N., 359  
Anisman, H., 57  
Arai, H., 769  
Arce, A., 789  
Asakura, W., 79  
Aulakh, C. S., 615, 759  
Ayres, J. J. B., 183
- Backon, J., 335  
Báez, M., 729  
Baeza, R., 819  
Baker, G. B., 177  
Ball, W. A., 93  
Barber, D. A., 579  
Bardo, M. T., 241  
Baskin, P. P., 437  
Baskys, A., 1105  
Bass, P. P., 1093  
Baumeister, A. A., 737  
Bednarczyk, J. M., 523  
Belmaker, R. H., 341  
Belzung, C., 433  
Benavente, F., 819  
Beninger, R. J., 363  
Berkowitz, R. J., 25  
Bersudsky, Y., 341  
Beuzen, A., 433  
Bevins, R. A., 183  
Beyer, C., 303  
Billington, C. J., 143, 377, 843  
Blackburn, T. P., 281  
Blatt, E. J., 1067  
Blick, D. W., 503  
Block, R. I., 1061  
Boag, P. T., 363  
Bodnar, R. J., 197, 205  
Bonnafous, C., 253  
Bonson, K. R., 313  
Bontemps, R., 777  
Borisenko, S. A., 33  
Borland, J. L., 1011  
Borowski, T. B., 935  
Borszcz, G. S., 827
- Botez, M. I., 777  
Boyson, S. J., 147  
Brioni, J. D., 755  
Briscoe, R. J., 1001, 1007  
Broderick, P. A., 711  
Brown, G. C., 503  
Brudzynski, S. M., 835  
Buccafusco, J. J., 1  
Buchanan, C. P., 483  
Bueno, L., 253  
Burke, K. A., 643  
Buxton, A., 1067
- Calamandrei, G., 1043  
Callan, O. A., 1067  
Carriero, D. L., 25  
Carro, E., 789  
Chait, L. D., 643  
Chan, A. W. K., 371  
Chen, P., 1061  
Chen, S.-W., 47  
Cheng, P. Y., 795  
Chernet, E., 7  
Chiu, T. H., 477  
Cleary, J., 143  
Coalson, D. W., 573  
Coen, K. M., 67  
Cohen, C., 455  
Cole, J. C., 985  
Corrigall, W. A., 67  
Cousins, M. S., 25, 85  
Criado, J. R., 413  
Cruz, A. P. M., 171  
Cunningham, K. A., 555  
Curzon, P., 877  
Czuczwar, S. J., 609
- Darmani, N. A., 229  
Das, S., 813  
Daud, M. M., 393  
Davies, M. F., 47  
Davis, T., 733  
De Acetis, L., 701  
De Castro, J. M., 629  
De Oliveira, L. M., 393  
Decker, M. W., 877  
DeFries, J. C., 531  
Della Seta, D., 701  
Derrien, M., 133  
Dewey, W. L., 1017  
Díaz-Véliz, G., 819  
Dib, B., 639  
Doi, C., 769  
Dose, J. M., 73  
Dringenberg, H. C., 741  
Du, W., 599  
Ducos, B., 133  
Duffy, R. A., 567
- Durazzo, T. C., 1001, 1007  
Durieux, C., 133  
Dussaubat, N., 819  
Duttaroy, A., 733  
Duvauchelle, C. L., 233
- El-Hwuegi, A., 801  
El-Zahaby, H. M., 1061  
Ellinwood, E. H., Jr., 883  
Elsohly, M. A., 187  
Eng, F., 711  
Engelman, K., 187  
Esquifino, A. I., 789  
Essman, W. D., 107
- Fahey, K. A., 827  
Feng, Y. Z., 649, 657  
Fernandes, C., 359  
File, S. E., 219, 359, 449, 625  
Finkelstein, J. E., 707  
Fiorella, D., 313  
Fischman, M. W., 763  
Fitten, L. J., 235  
Florio, C., 271  
Fluck, E., 449  
Foltin, R. W., 763  
Fong, C.-S., 147  
Fontana, D. J., 1067, 1075  
Fowler, S. C., 813  
Frei, F., 171  
Friedhoff, A. J., 663  
Fu, X.-W., 835  
Fujimoto, J. M., 675  
Fuller, R. D., 737
- Galbicka, G., 943  
Gandolfo, G., 921  
Gauvin, D. V., 223, 1001, 1007  
Gendron, T. M., 583  
Genkova-Papazova, M., 849  
Gewiss, M. V., 589  
Geyer, M. A., 155  
Ghoneim, M. M., 1061  
Gianutsos, G., 437  
Gibson, T. R., 241  
Gilhar, D., 335  
Goldberg, S. R., 41, 589  
Gómora, P., 303  
Gondoh, Y., 905  
González-Mariscal, G., 303  
Gordon, C. J., 747  
Gorelick, D. A., 583  
Gottesmann, C., 921  
Goulden, K. L., 223, 1001, 1007  
Graeff, F. G., 171, 549  
Gray, J. A., 511  
Griffiths, J., 57
- Grigoryan, G. A., 511  
Grilly, D. M., 497  
Grisel, J. E., 1029  
Guan, X.-M., 7  
Gümüsel, B., 891  
Guo, X. Y., 583
- Hafen, T., 975  
Halgren, E., 235  
Harper, D. N., 427  
Harro, J., 801  
Hartgraves, S. L., 503  
Hartle, D. K., 489  
Harvey, J. A., 599  
Hasan, M., 443  
Hasegawa, T., 807  
Hashemi, T., 567  
Hawkins, M. F., 737  
Henderson, N. D., 531  
Hendricks, S. E., 121  
Hengemihle, J. M., 707  
Henningfield, J. E., 583  
Henriksen, S. J., 413  
Herning, R. I., 583  
Hill, J. L., 615, 759  
Hill, W. L., 483  
Hillegaart, V., 101  
Ho, I. K., 649, 657  
Hobbs, D. J., 197  
Hodges, H., 511  
Hoffer, B. J., 147  
Hoffman, A., 335  
Hogg, S., 219, 625  
Holloway, F. A., 223, 1001, 1007  
Holmes, B. B., 675  
Homma, I., 669  
Hong, E., 1083  
Hope, H., 1101  
Hoskins, B., 649, 657  
Hubert, I., 683  
Hudson, J. L., 147  
Hughes, R. A., 1011  
Humentuk, R. E., 561  
Husain, R., 443  
Hussong, M. J., 129
- Ido, H., 165  
Ikasaki, Y., 769  
Ikeda, K., 19  
Ikemoto, S., 327  
Il'ina, A. D., 1109  
Imaizumi, M., 471  
Inazu, M., 669  
Ingram, D. K., 707  
Inoue, T., 911  
Inouye, G. T., 1075  
Ishibashi, T., 19

- Ishida, K., 19  
 Itoh, A., 807  
  
 Jaffard, R., 689  
 Jagers, T., 943  
 Jähkel, M., 263  
 Järvikylä, M., 853  
 Jaw, S. P., 129, 649  
 Johnson, C. P., 827  
 Johnson, R. G., 313  
 Johnson, R. M., 1075  
 Jørgensen, H. A., 309  
 Jou, M.-J., 405  
 Joyner, C., 883  
 Jung, J.-S., 1037  
  
 Kalynchuk, L. E., 1113  
 Karmanova, I. G., 277  
 Katono, Y., 807  
 Kautz, M. A., 943  
 Kayaalp, S. O., 891  
 Kayaalp, S. O., 969  
 Kelly, T. H., 763  
 Kennett, G. A., 281  
 Kido, H., 165  
 Kim, D. J. B., 877  
 Kim, Y.-H., 1037  
 King, G. R., 883  
 Kippin, T. E., 1113  
 Kiviranta, T., 997  
 Kiyatkin, E. A., 247  
 Kleinrok, Z., 609  
 Kling-Petersen, T., 345  
 Klodt, P. M., 1109  
 Knapp, C. M., 901  
 Koch, J. E., 197, 205  
 Koeppl, B., 583  
 Kofman, O., 341  
 Kokkinidis, L., 935  
 Kornelsen, R. A., 741  
 Kornetsky, C., 233, 901  
 Kostal, L., 295  
 Koyama, T., 911  
 Kozlachkova, E. Y., 277  
 Kulikov, A. V., 277  
 Kundu, G. C., 621  
 Kuribara, H., 323  
 Kuroda, Y., 961  
 Kutepova, O., 33  
  
 Lafuente, A., 789  
 Lalonde, R., 777  
 Lankford, M. F., 417  
 Laviola, G., 871  
 Lazarova-Bakarova, M., 849  
 Leander, J. D., 385  
 Lecklin, A., 853  
 Lenègre, A., 683  
 Levine, A. S., 143, 377, 843  
 Li, M., 477  
 Li, T.-K., 7  
 Lichtor, J. L., 573  
 Lightowler, S., 281  
 Ljung, E., 345  
 Loew, G. H., 47  
 Loh, E. A., 177  
 López, M., 789  
 Loron, P., 777  
 Lucki, I., 107  
 Lumeng, L., 7  
  
 Machida, H., 471  
 Maguire, P. A., 47  
 Maier, S. F., 1029  
 Maisky, A. I., 1109  
 Mann, G. L., 93  
 Männistö, P. T., 33  
 Marcó, J., 789  
 Marighetto, A., 689  
 Marks, M. J., 531  
 Marley, R. J., 589  
 Marmarosh, N., 405  
 Maruyama, Y., 769  
 Matsuguchi, N., 905  
 Matsumoto, K., 13, 79, 213  
 Matsumoto, R. R., 129  
 Mattes, R. D., 187  
 Maurice, T., 859  
 Mayr, M. T., 763  
 McBride, W. J., 7  
 McCallum, M. D., 737  
 McCormick, T. M., 1011  
 McCort-Tranchepain, I., 133  
 McCullough, L. D., 25  
 McIntyre, C. P., 1113  
 McLaughlin, C. R., 1017  
 McQuade, R. D., 567  
 Meguro, K., 769  
 Melchers, B. P. C., 781  
 Meneses, A., 1083  
 Micheau, J., 689  
 Mikuni, M., 961  
 Milinkevich, D., 683  
 Miller, M., 955  
 Miller, S., 257  
 Mills, A., 625  
 Mineau, P., 363  
 Misslin, R., 433  
 Mitchell, S. N., 511  
 Miyazaki, S., 471  
 Mizoguchi, K., 905  
 Mora, S., 819  
 Mori, H., 165  
 Mori, K. J., 961  
 Morrison, A. R., 93  
 Muneoka, K., 961  
 Murphy, D. L., 615, 759  
 Murphy, M. R., 503  
 Myers, R. D., 417, 949  
  
 Nabeshima, T., 807, 859  
 Nakamura, M., 19, 121  
 Nakamura, T., 769  
 Narita, M., 657  
 Navarro, E., 353  
 Nelson, E., 327  
 Nikulina, E. M., 985  
 Nitta, A., 807  
  
 Oehler, J., 263  
 Ogawa, T., 961  
 Ohno, Y., 19  
 Ohta, H., 13, 79, 213  
 Ojima, K., 13  
 Okada, K., 19  
 Okorodudu, A. O., 1087  
 Onaivi, E. S., 47  
 O'Neill, A. B., 755  
 O'Neill, J., 235  
 Ong, J., 561  
 Oreland, L., 801  
 Orozco, S., 629  
  
 Palumbo, P. A., 115  
 Panksepp, J., 327  
 Paris, J. M., 555  
 Parish, D. W., 859  
 Parker, B. K., 955  
 Parrott, R. F., 463  
 Paterson, S., 625  
 Pauly, J. R., 1  
 Perryman, K. M., 235  
 Persico, A. M., 41  
 Pert, A., 399  
 Petkov, V. D., 849  
 Petri, H. L., 707  
 Petruzzi, S., 871  
 Phelan, F. T., 711  
 Philippens, I. H. C. H. M., 781  
 Pickworth, W. B., 583  
 Pierce, T. L., 1101  
 Pineau, N., 433  
 Pinel, J. P. J., 1113  
 Pinto, E., 335  
 Popova, N. K., 277  
 Porsolt, R. D., 683  
 Prendergast, M. A., 121  
 Privat, A., 859  
 Prospero-García, O., 413  
 Pugh, G., Jr., 1093  
  
 Rabin, R. A., 313  
 Rady, J. J., 675  
 Rankin, J., 871  
 Reynolds, F. A., 233  
 Roberts, D. C. S., 177  
 Rodgers, R. J., 985  
 Rodriguez, M., 353  
 Roliński, Z., 609  
 Romaniuk, A., 541  
 Romano, A. G., 599  
 Roques, B. P., 133  
 Rosati, A. M., 271  
 Rosenberg, H. C., 477  
 Rosengarten, H., 663  
 Ross, R. J., 93  
 Rossi, R., 897  
 Rothman, R. B., 399, 583  
 Roux, S., 683  
 Rowland, N. E., 287  
 Rowlett, J. K., 241  
 Rudski, J. M., 143, 377, 843  
  
 Sakai, Y., 669  
 Sakamoto, H., 165  
 Salamone, J. D., 25, 85, 437  
 Sanford, L. D., 93  
 Sanger, D. J., 455  
 Santucci, L. B., 393  
 Sasaki, H., 769  
 Savory, C. J., 295  
 Scarpace, P. J., 1057  
 Schaal, D. W., 143, 955  
 Schaefer, L. A., 205  
 Scharrer, E., 897  
 Scherschlicht, R., 921  
 Schindler, C. W., 41, 589  
 Schullek, J. R., 621  
 Schumacher, H.-E., 263  
 Schweitzer, J. W., 663  
 Seggos, A. E., 93  
 Seth, P. K., 443  
 Shah, S., 733  
  
 Shamoto, A., 669  
 Shanks, N., 57  
 Shapiro, Y., 341  
 Sharma, V., 405  
 Shaw, L. M., 187  
 Sherif, F., 801  
 Sheu, S.-S., 405  
 Shiba, K., 165  
 Shimizu, M., 213  
 Shimizu, T., 905  
 Shrier, E. M., 483  
 Simon, B. B., 497  
 Sinden, J. D., 511  
 Singh, A., 107  
 Smolen, A., 531  
 Song, D.-K., 1037  
 Soong, Y., 795  
 Su, T.-P., 859  
 Sufka, K. J., 1011  
 Suh, H.-W., 1037  
 Sumiyoshi, T., 165  
 Sunal, R., 891  
 Suzuki, K., 165  
 Svensson, K., 345  
 Swerdlow, N. R., 155  
 Szeto, H. H., 795  
  
 Tackett, R. L., 579  
 Takahashi, K., 961  
 Tanaka, M., 905  
 Taylor, L. A., 567  
 Thapar, P., 573  
 Thompson, T., 143  
 Thomson, L. E., III, 583  
 Thorndike, E. B., 589  
 Tian, B., 489  
 Tice, M. A. B., 567  
 Tolliver, T., 615  
 Tomaz, C., 549  
 Traversa, U., 271  
 Truong, D. D., 129  
 Tsai, N. F., 47  
 Tseng, Y. T., 649, 657  
 Tsuchiya, K., 911  
 Tsuda, A., 905  
 Tuimisto, L., 853  
 Tulloch, I. F., 281  
 Tümer, M., 1057  
 Tuomainen, P., 33  
 Tuomisto, L., 997  
  
 Uhl, D. R., 41  
 Urasaki, K., 165  
 Uvns-Moberg, K., 101  
 Uzbay, I. T., 969  
  
 Valanzano, A., 1043  
 Vanderwolf, C. H., 741  
 Vertua, R., 271  
 Viana, M. B., 549  
 Vickers, G., 177  
 Volosin, M., 729  
 Voronina, T., 33  
 Voronova, I. P., 277  
  
 Wan, F. J., 155  
 Wang, D. X., 405  
 Watanabe, H., 13, 79, 213  
 Watkins, L. R., 1029  
 Watson, J. E., 427



Wechsler, R. T., 711  
Wehner, J. M., 257  
Weinger, M. B., 523  
Welch, S. P., 929, 1093  
Wessinger, W. D., 1049  
White, J. M., 561  
White, K. G., 427  
Wieczorek, M., 541  
Wiertelak, E. P., 1029  
Wiley, J. L., 1025

Williamson, I. J. R., 281  
Wilson, I. B., 621  
Winter, J. C., 115, 313  
Właź, P., 609  
Wojtowicz, J. M., 1105  
Wolff, M. C., 385  
Wollnik, F., 975  
Wolthuis, O. L., 781  
Wong, E. H. F., 1067  
Wozniak, K. M., 615

Wu, D.-L., 795  
Yajnik, S., 573  
Yamada, M., 769  
Yamaguchi, N., 165  
Yamaguchi, S., 769  
Yang, X., 1  
Yells, D. P., 121  
Yenice, S., 1057  
Yoburn, B. C., 733

Yokoo, H., 905  
York, J. L., 371  
Yukhananov, R. Y., 1109  
Zacny, J. P., 573  
Zagrodzka, J., 541  
Zaitsev, S. V., 1109  
Zhu, B., 669  
Zolman, J. F., 73  
Zolotov, N., 33